Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

Read About Our Alliance

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

New Treatment Candidate

COVID-19 Update: CSL continues to provide medicines to patients around the world.

Learn More

Popular search terms:

Paul Perreault

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

red text logo for CSL Behring

CSL Behring Begins Trial for Respiratory Distress

Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe res…

06 Jul 2020
CSL Logo

COVID-19 Update

CSL continues to provide medicines to patients around the world.

30 Jun 2020
red text logo for CSL Behring

CSL Behring Gene Therapy Agreement with uniQure

Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits w…

24 Jun 2020

Get to Know Us Better

Scientists in Marburg, Germany
Analytical Services Quality Employee Angelika Jung

Angelika Jung

Senior Manager, ASQ Group Leader External Materials & Sampling (Marburg, Germany)

Angelika has been with CSL Behring for nearly 20 years and in that time has grown from having no direct reports to leading a large team in our Quality group.

Watch Angelika's Story